Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
AlzeCure’s abstract on ACD856’s anti-inflammatory effects to be presented at a leading Alzheimer’s conference
October 1, 2024
-
AlzeCure publishes its interim report for January – June 2024
August 26, 2024
-
New scientific article on NeuroRestore ACD856 and its improved cognition and disease modification of Alzheimer’s disease
August 13, 2024